Sherwood J E, Mauser P J, Chapman R W
Department of Allergy, Schering-Plough Research Institute, Kenilworth, New Jersey 07033-0539, USA.
J Pharmacol Exp Ther. 1997 Nov;283(2):788-93.
Neurokinin A (NKA) is the primary bronchoconstrictor tachykinin in the lungs of several species, including humans and has been implicated as an important mediator of inflammatory lung disorders, such as asthma. In this study, we investigated the effect of NKA on airway mechanics (lung resistance, dynamic lung compliance) and respiration (tidal volume, respiratory rate) in anesthetized, spontaneously breathing, male beagle dogs. The dogs were challenged with aerosolized NKA that was delivered from a jet nebulizer to the airways through an endotracheal tube. The challenge consisted of five separate inflations of 600 ml of air/inflation over a 1-min period. Challenge with aerosolized NKA (0.1-1%) produced a dose-dependent increase in lung resistance and a decrease in dynamic lung compliance. The bronchoconstriction induced by 1% NKA peaked at 0.5 min after challenge and had a duration of approximately 5 min. Challenge with 1% NKA also reduced tidal volume and increased respiratory rate. Pretreatment of dogs with the NK-2 receptor antagonist, SR 48968 dose-dependently (1-10 mg/kg, p.o.) blocked the bronchoconstriction and respiratory responses to NKA challenge. Pretreatment with the NK1-receptor antagonist, CP 99994 (1 mg/kg, i. v.) had no effect on the increase in lung resistance and the decrease in dynamic lung compliance due to NKA challenge, but blunted the respiratory response to NKA. Pretreatment of dogs with inhaled ipratropium bromide (0.01%) slightly, but significantly reduced the increase in lung resistance due to NKA challenge but had no effect on the decrease of dynamic lung compliance or on the respiratory responses to NKA. As expected, the bronchoconstrictor response to inhaled methacholine was completely blocked by inhaled ipratropium bromide (0.01%). In conclusion, we have identified an NK2-receptor mediated bronchoconstrictor effect of NKA in dogs. Cholinergic reflexes play a small, but significant role in this response. Furthermore, both NK1 and NK2-receptors appear to be involved with the development of the rapid, shallow breathing response to NKA challenge. These results demonstrate an effect of tachykinins on airway mechanics and ventilatory reflexes in dogs.
神经激肽A(NKA)是包括人类在内的多种物种肺部主要的支气管收缩速激肽,并且被认为是炎症性肺部疾病(如哮喘)的重要介质。在本研究中,我们调查了NKA对麻醉状态下自主呼吸的雄性比格犬气道力学(肺阻力、动态肺顺应性)和呼吸(潮气量、呼吸频率)的影响。通过气管内导管将雾化的NKA从喷射雾化器输送至气道来对犬进行激发试验。激发试验包括在1分钟内分5次每次注入600ml空气。雾化NKA(0.1 - 1%)激发试验导致肺阻力呈剂量依赖性增加,动态肺顺应性降低。1% NKA诱发的支气管收缩在激发后0.5分钟达到峰值,持续时间约为5分钟。1% NKA激发试验还降低了潮气量并增加了呼吸频率。用NK - 2受体拮抗剂SR 48968(1 - 10mg/kg,口服)对犬进行预处理可剂量依赖性地阻断对NKA激发试验的支气管收缩和呼吸反应。用NK1受体拮抗剂CP 99994(1mg/kg,静脉注射)预处理对因NKA激发试验导致的肺阻力增加和动态肺顺应性降低没有影响,但减弱了对NKA的呼吸反应。用吸入性异丙托溴铵(0.01%)对犬进行预处理可轻微但显著降低因NKA激发试验导致的肺阻力增加,但对动态肺顺应性降低或对NKA的呼吸反应没有影响。正如预期的那样,吸入性异丙托溴铵(0.01%)完全阻断了对吸入性乙酰甲胆碱的支气管收缩反应。总之,我们确定了NKA在犬中存在由NK2受体介导的支气管收缩作用。胆碱能反射在该反应中起小但显著的作用。此外,NK1和NK2受体似乎都参与了对NKA激发试验快速、浅呼吸反应的形成。这些结果证明了速激肽对犬气道力学和通气反射的影响。